RC48+Carboplatin+Bevacizumab

Phase 2Monoclonal antibody

PPeking University Cancer Hospital & Institute

RC48+Carboplatin+Bevacizumab is one of 61 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CarcinomaRecruiting

Ovarian CancerRecruiting

Ovarian CarcinomaPhase 2

Recruiting

Ovarian CancerPhase 2

Recruiting

Competition

Competitive Landscape

209 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

92 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Keytruda

Merck & Co.

Phase 3

28 4

Hycamtin

MMeitheal

Phase 3

26 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 6

Imfinzi

AstraZeneca

Phase 3

8 7

Femara

Novartis

Phase 3

8 8

Opdivo

Bristol-Myers Squibb

Phase 3

8 9

Adriamycin

Pfizer

Phase 3

8 10

Rubraca

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Ovarian Carcinoma

NCT06420973

Q4 2028

Phase 2Recruiting

Ovarian Cancer

NCT07311577

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07311577·43 enrolled

Ovarian Carcinoma1 trial

A Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06420973·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RC48+Carboplatin+Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RC48+Carboplatin+Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RC48+Carboplatin+Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: PPeking University Cancer Hospital & Institute

RC48+Carboplatin+Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Ovarian Cancer1 trial

Ovarian Carcinoma1 trial

References

Drug Info

Quick Facts

Related News